{"prompt": "['Novartis', 'Confidential', 'Page 31', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'Medication', 'Prohibition period (Minimum cessation prior to Run-in)', 'Leukotriene receptor antagonists (LTRA)', 'Stopped at beginning of Run-in period', '6.2.3', 'Rescue medication', 'At the start of the Run-in period, all patients will be provided with a SABA (such as salbutamol', '100 mcg or albuterol 90 mcg) which they will be instructed to use throughout the study as rescue', \"medication on an 'as needed basis'. Patients will be advised that between visits they could take\", 'their rescue medication for symptoms of asthma. Rescue medication (i.e., SABAs) will either', 'be supplied to the Investigator sites locally by the Novartis country pharma organization (CPO)', 'or sourced locally and reimbursed by Novartis. Nebulized salbutamol/albuterol is not allowed', 'as rescue medication and will not be supplied.', 'Should patients develop any sino-nasal exacerbations during the course of the study, the treating', 'physician should follow their normal treatment regimen with systemic corticosteroids and/or', 'antibiotics. Short term oral or nasal decongestants may also be utilised as a rescue therapy', 'however the assessment of NPS must not be performed within 3 days of their use.', 'Use of rescue medication must be recorded on the concomitant medications in the CRF.', '6.3', 'Subject numbering, treatment assignment, randomization', '6.3.1', 'Subject numbering', 'Each subject is identified in the study by a Subject Number (Subject No.), that is assigned when', 'the patient is first enrolled for screening and is retained as the primary identifier for the subject', 'throughout his/her entire participation in the trial. The Subject No. consists of the Center', 'Number (Center No.) (as assigned by Novartis to the investigative site) with a sequential subject', 'number suffixed to it, so that each subject is numbered uniquely across the entire database.', 'Upon signing the informed consent form, the patient is assigned to the next sequential Subject', 'No. available.', '6.3.2', 'Treatment assignment, randomization', 'At randomization visit, all eligible subjects will be randomized via Interactive Response', 'Technology (IRT) to one of the treatment arms. The Investigator or his/her delegate will contact', 'the IRT after confirming that the patient fulfills all the inclusion/exclusion criteria. The IRT', 'will assign a randomization number to the patient, which will be used to link the patient to a', 'treatment arm and will specify unique medication numbers for the first packages of study drug', 'to be dispensed to the patient. The randomization number will not be communicated to the caller.', 'The randomization numbers will be generated using the following procedure to ensure that', 'treatment assignment is unbiased and concealed from subjects and Investigator staff. A patient', 'randomization list will be produced by the IRT provider using a validated system that automates', 'the random assignment of patient numbers to randomization numbers. These randomization', 'numbers are linked to the different treatment arms, which in turn are linked to medication', 'numbers. A separate medication list will be produced by or under the responsibility of Novartis', 'Global Clinical Supplies using a validated system that automates the random assignment of', 'medication numbers to packs containing the investigational drug(s).']['Novartis', 'Confidential', 'Page 32', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'The randomization scheme for subjects will be reviewed and approved by a member of the', 'Randomization Group.', '6.4', 'Treatment blinding', 'Subjects, Investigator staff, persons performing the assessments, and clinical trial team (CTT)', 'will remain blind to the identity of the treatment from the time of randomization until database', 'lock, using the following methods: (1) Randomization data are kept strictly confidential until', 'the time of unblinding, and will not be accessible by anyone else involved in the study, (2) the', 'identity of the treatments will be concealed by the use of study treatment that are all identical', 'in packaging, labeling, schedule of administration, appearance, taste and odor.', 'A double-dummy design is used because the identity of the study treatment cannot be disguised,', 'as the drug products are visibly different.', 'Unblinding will occur in the case of subject emergencies and at the conclusion of the study.', 'Table 6-3', 'Blinding and unblinding plan', 'Time or Event', 'Role', 'Randomization list', 'Treatment allocation', 'Safety event (single', 'generated', '& dosing', 'subject unblinded)', 'Subjects', 'B', 'B', 'B', 'Site staff', 'B', 'B', 'B', 'Unblinded site staff e.g. pharmacy', 'B', 'B', 'B', 'staff (specify)', 'Drug Supply and Randomization', 'UI', 'UI', 'UI', 'Office', 'Unblinded Pharmacovigilance', 'UI', 'UI', 'UI', 'sponsor staff', 'Statistician/statistical programmer/', 'B', 'B', 'B', 'data analysts (e.g. biomarker, PK)', 'Independent committees used for', 'NA', 'NA', 'NA', 'assessing interim results, if', 'required (e.g. DMC)', 'All other sponsor staff not', 'B', 'B', 'B', 'identified above (trial team, project', 'team, management & decision', 'boards, support functions)', 'Key:', 'UI: Allowed to be unblinded on individual subject level', 'B: Remains blinded', 'NA: Not applicable to this study', '6.5', 'Dose escalation and dose modification', 'Investigational or other study treatment dose adjustments and/or interruptions are not permitted', 'and should any such changes in dosing regimen occur during the study then the patients will be', 'excluded unless highlighted as a rescue therapy within other sections of the protocol.']\n\n###\n\n", "completion": "END"}